<DOC>
	<DOCNO>NCT00077259</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy epothilone D work different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well epothilone D work second-line therapy treat patient advanced metastatic refractory colorectal cancer .</brief_summary>
	<brief_title>Epothilone D Second-Line Treatment Patients With Advanced Metastatic Refractory Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity epothilone D second-line treatment , term objective response rate , patient advance metastatic refractory colorectal cancer . Secondary - Determine safety drug patient . - Determine response duration patient respond treatment drug . - Determine time tumor progression overall survival patient treated drug . - Correlate efficacy safety plasma concentration drug major metabolite patient . OUTLINE : This open-label , multicenter study . Patients receive epothilone D IV 90 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 19-69 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic adenocarcinoma colon rectum Evidence least 1 site unidimensionally measurable disease radiography physical examination Failed 1 prior treatment fluoropyrimidine combination either irinotecan OR oxaliplatin advance metastatic disease No known CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Alkaline phosphatase ≤ 5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No New York Heart Association class III IV congestive heart failure No QTc &gt; 450 msec male &gt; 470 msec females No personal family history congenital long QT syndrome Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No preexisting neuropathy grade 2 great No document grade 3 4 hypersensitivity reaction prior therapy contain Cremophor No infection require parenteral oral antiinfective treatment No alter mental status psychiatric condition would preclude give informed consent No medical condition would preclude study participation No malignancy within past 5 year except cure basal cell skin cancer , carcinoma situ cervix bladder , stage T1 T2 prostate cancer prostatespecific antigen &lt; 2 ng/mL PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent sargramostim ( GMCSF ) No concurrent routine prophylactic use filgrastim ( GCSF ) Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy recover Surgery At least 3 week since prior surgery recover Other More 3 week since prior investigational agent ( therapeutic diagnostic ) No concurrent therapy advance metastatic colorectal cancer No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>